Letters GLP-1R agonists and weight loss

Authors’ reply to de Oliveira and Iverson

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e1459 (Published 28 February 2012) Cite this as: BMJ 2012;344:e1459
  1. Tina Vilsbøll, associate professor and chief consultant endocrinologist1,
  2. Mikkel Christensen, specialist registrar1,
  3. Anders E Junker, registrar1,
  4. Filip K Knop, associate professor and specialist registrar1,
  5. Lise Lotte Gluud, consultant hepatologist1
  1. 1Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark
  1. t.vilsboll{at}dadlnet.dk

We found that glucagon-like peptide-1 receptor (GLP-1R) agonists suppress appetite and lead to clinically beneficial weight loss, improved glycaemic control (in patients with type 2 diabetes), and reduced blood pressure and cholesterol values over 20 weeks1—clinically relevant treatment results.2 The effect is sustained for up to two years in most patients.3 Several large cardiovascular outcome trials, each of up …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe